Previous 10 | Next 10 |
HeartBeam (NASDAQ: BEAT) , a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, today announced that it will hold a conference call at 4:30 p.m ET on Thursday, Nov. 10, 2022. HeartBeam CEO and Founder Branisl...
HeartBeam, Inc . (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, will hold a conference call on Thursday November 10, 2022 at 4:30 p.m. Eastern time to discuss its results for the...
HeartBeam (NASDAQ: BEAT) recently received a patent from the United States Patent and Trademark Office for its 12-lead electrocardiogram (“ECG”) patch monitor for the detection of acute coronary syndrome (“ACS”) and cardiac arrhythmia. “The new patent exp...
A new case-series study has discovered that gaming can trigger deadly heart arrhythmias in children. Heart arrhythmias are irregular heartbeats that occur when the electrical signals coordinating the beating of an individual’s heart aren’t working properly. The researcher...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Short-squeeze stocks continue to be a big deal for speculative traders and we’re helping them out with a list to keep in mind this week! That list comes from Fintel and its Short Sque...
HeartBeam (NASDAQ: BEAT) , a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, is slated to present at this month’s LD Micro Main Event XV Conference. Scheduled for Oct. 25–27, 2022, the three-...
HeartBeam, Inc . (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, will present at the LD Micro Main Event XV Conference being held at the Luxe Sunset Boulevard Hotel in Los Angeles...
New research has found that drinking two to three cups of coffee a day may protect an individual from cardiovascular illness and even an early death. Peter Kistler, head of clinical electrophysiology research at the Baker Heart and Diabetes Institute and author of the study, stated that fi...
HeartBeam ( NASDAQ: BEAT ) appoints renowned Stanford cardiologist Peter J. Fitzgerald, MD, PhD, as Chief Medical Officer. Dr. Fitzgerald is the Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory at St...
Renowned Stanford Cardiologist Brings Deep Clinical, Research, and Industry Expertise to Executive Team HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, tod...
News, Short Squeeze, Breakout and More Instantly...
HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has been added to the Russell Microcap(R) Index. The move was effective after market close on June 28, 2024, and is part of FTSE Russell’s annual reconst...
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced that it has been added to the Russell Microcap® Index effective after the market close on June 28, 2024 as part of FTSE Russell...
HeartBeam (NASDAQ: BEAT) , a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced the results of a new study demonstrating that HeartBeam AI combined with vectorcardiography (“VCG”) outperformed an expert panel o...